August 8, 2016 6:37am
… The sector could be challenged as low volume enhances pricing risk and trading patterns muddy the waters
Financial results/earnings will broaden the perspective this week … ATHX, BLFS, BLCM, BSTG, BTX, CLBS, HSGX, FATE, KITE, ONCE, STML, VCEL, VSTM and XON
… Reiterating, I could be feeling some “burn” next week as the NASDAQ has set new highs
I answer one question; in which company should investors put, keep and commit their money!
Where is today’s market going? Subscribe and find out!
Where do investors turn for insight and perspective - I say truthfully what others won't, so you can do what others can't!
Companies in my headlights: CLLS, JUNO and XON
Indexes and ETFs: The IBB (+0.24%) the IWM (+0.23%) are UP while the XBI (-0.30%) and XLV (-0.01%) are DOWN
Dow futures are UP +0.21% and NASDAQ futures are UP +0.29%
U.S. stocks poised for more highs, with futures moving higher as investors continue to take inspiration from last week’s solid U.S. jobs data.
European stocks traded higher but investors remain cautious after weak Chinese trade data and consider if the latest U.S. jobs numbers could trigger an interest rate hike by the Federal Reserve this year.
Asia markets advanced, shrugging off weak Chinese trade data. China's exports and imports fell more-than-expected in dollar-denominated terms in July, which could revive concerns over the economic outlook for the world's second largest economy both at home and abroad.
Data docket: There is no major economic data on the calendar for Monday.
The stem, cell, gene and regenerative therapy (SCG&RT) sector closed POSITIVE on Friday, NEGATIVE on Thursday, POSITIVE on Wednesday, NEGATIVE on Tuesday, POSITIVE on last Monday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
- Friday closed POSITIVE with 11 decliners, 29 advancers and 3 flats;
- Thursday closed NEGATIVE with 23 decliners, 19 advancers and 1 flat;
- Wednesday closed POSITIVE with 7 decliners, 33 advancers and 3 flats;
- Tuesday closed NEGATIVE with 26 decliners, 15 advancers and 2 flats;
- Last Monday closed POSITIVE with 19 decliners, 21 advancers and 3 flats;
Remembering Friday’s post, “Regardless of losses, investors face the same problem each quarter — the obsession among analysts and the media with “beating” quarterly estimates for earnings or revenues. Beating an estimate is part of the traditional “game”, but it might not tell you anything about how a development company is doing or what it needs to do.”
Reporting Monday are Intrexon (XON), Fate Therapeutics (FATE) and Vericel (VCEL) …
What does it take to be a stem, cell, gene and regenerative therapy investor?
- The ability to tune out the “noise” and objectively weigh alternating sentiment.
I am one who thinks that trading in opposition or contrary to what is generally understood or practiced should be thoroughly adapted in this frothy sector as a rule.
Shorter-term, “our” universe may appreciate after financial results/earning’s divergences!
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) closed Friday up +0.38% and is UP +$0.24 in Monday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) closed Friday up +1.09% and is DOWN -0.30% in Monday’s pre-market;
- .The Health Care Select Sector SPDR ETF (XLV) closed up Friday +0.24% and is DOWN -0.01% in Monday’s pre-market;
- The iShares Russell 2000 (IWM) closed up +1.44% on Friday and is UP +0.23% in Monday’s pre-market.
Companies in my headlights:
Cellectis SA (CLLS) closed UP +$0.66 to $28.35. August began at $27.10, July began at $27.25 and June began at $32.51 - NO specific reason other than being oversold. The aftermarket indication is positive +$1.15 or +4.06% to $29.50, - BUY
Juno Therapeutics (JUNO) closed UP +$0.54 to $31.46 after Thursday’s $30.92 (-$0.39). The aftermarket indication is negative -$0.42 – BUY to SELL;
Intrexon (XON) closed UP +$1.03 to $28.71 after Thursday’s $27.68 (-$0.71). A growing Zika outbreak in Florida has forced public health officials to issue a rare domestic travel warning, urging pregnant women — and those trying to have a child — to avoid a trendy section of the city where the virus has been spreading. Zika has not been contained and is spreading. What defenses other than spraying are there? The state of Florida could soon be freeing genetically modified mosquitoes to combat the Zika virus. The aftermarket indication is positive +$0.49 – Maintaining BUY
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
